Polyneuropathy, Amyloid

Neurology
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

C
CENTOGENEGermany - Rostock
1 program
Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR FAP)N/A1 trial
Active Trials
NCT01705626Completed500Est. May 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CENTOGENEScreening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR FAP)

Clinical Trials (1)

Total enrollment: 500 patients across 1 trials

NCT01705626CENTOGENEScreening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR FAP)

Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR FAP)

Start: Dec 2016Est. completion: May 2022500 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
7h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
7h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
7h ago

Director of Finance

CoMind
London, UK
7h ago

Electronics Engineering Manager

CoMind
London, UK
7h ago

Director of Information Technology

Zavation Medical Products
7h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)